AR039628A2 - Formulacion masticable de carprofeno, implante y composicion terapeutica - Google Patents
Formulacion masticable de carprofeno, implante y composicion terapeuticaInfo
- Publication number
- AR039628A2 AR039628A2 ARP030101251A ARP030101251A AR039628A2 AR 039628 A2 AR039628 A2 AR 039628A2 AR P030101251 A ARP030101251 A AR P030101251A AR P030101251 A ARP030101251 A AR P030101251A AR 039628 A2 AR039628 A2 AR 039628A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- implant
- formulation
- carprophene
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000007943 implant Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- -1 amino, hydroxyamino Chemical group 0.000 abstract 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 abstract 1
- 229960003184 carprofen Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación masticable, un implante y una composición que comprenden carprofeno. Una composición caracterizada porque comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (1), en la que, R2 es -(CXY)n-C(O)-A, donde A es hidroxi, alcoxi (C1-4), amino, hidroxiamino, mono-alquilamino(C1-2), di-alquilamino(C1-2); X e Y son, independientemente, H o alquilo(C1-2); y n es 1 ó 2; R6 es halógeno, alquilo (C1-3), trifluorometilo o nitro; R9 es H; alquilo(C1-2); fenilo o fenil-alquilo(C1-2), donde el fenilo está opcionalmente mono-sustituido con fluoro o cloro; -C(=O)-R, donde R es alquilo(C1-2) o fenilo, opcionalmente mono-sustituido con fluoro o cloro; o -C(=O)-O-R1, donde R1 es alquilo(C1-2); donde X e Y son diferentes, los enantiómeros (-)(R) y (+)(S) de los mismos; y todas las formas de sales farmacéuticamente aceptables, profármacos y metabolitos de los mismos, en una forma de dosificación controlada que sea capaz de mantener los niveles de plasma por sobre aproximadamente 10 micro g/ml durante un período mayor a 10,5 horas. Estos son útiles en el tratamiento del dolor y de la inflamación con una menor incidencia de efectos secundarios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039628A2 true AR039628A2 (es) | 2005-03-02 |
Family
ID=21939053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (es) | 1997-05-05 | 1998-05-05 | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento |
| ARP030101251A AR039628A2 (es) | 1997-05-05 | 2003-04-09 | Formulacion masticable de carprofeno, implante y composicion terapeutica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (es) | 1997-05-05 | 1998-05-05 | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (es) |
| JP (1) | JP2000513020A (es) |
| KR (2) | KR20040004406A (es) |
| CN (1) | CN1255059A (es) |
| AP (1) | AP9801234A0 (es) |
| AR (2) | AR011726A1 (es) |
| AU (1) | AU6932198A (es) |
| BG (1) | BG103852A (es) |
| BR (1) | BR9808720A (es) |
| CA (1) | CA2288759A1 (es) |
| DZ (1) | DZ2479A1 (es) |
| EA (1) | EA003696B1 (es) |
| GT (1) | GT199800063A (es) |
| HR (1) | HRP980244A2 (es) |
| HU (1) | HUP0001286A3 (es) |
| ID (1) | ID21311A (es) |
| IL (1) | IL132570A0 (es) |
| IS (1) | IS5220A (es) |
| MA (1) | MA26491A1 (es) |
| NO (1) | NO995389L (es) |
| NZ (1) | NZ500183A (es) |
| OA (1) | OA11213A (es) |
| PA (1) | PA8450601A1 (es) |
| PE (1) | PE72599A1 (es) |
| PL (1) | PL337003A1 (es) |
| SK (1) | SK148199A3 (es) |
| TN (1) | TNSN98059A1 (es) |
| TW (1) | TW590773B (es) |
| UY (1) | UY24989A1 (es) |
| WO (1) | WO1998050033A1 (es) |
| YU (1) | YU55899A (es) |
| ZA (1) | ZA983722B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| US6506785B2 (en) | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| JP2002528413A (ja) * | 1998-10-23 | 2002-09-03 | メルク フロスト カナダ アンド カンパニー | Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法 |
| ATE306263T1 (de) * | 1999-03-10 | 2005-10-15 | Searle Llc | Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere |
| WO2001034204A1 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| CA2407469A1 (en) * | 2000-05-15 | 2001-11-22 | Merck Frosst Canada & Co. | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| KR20030019422A (ko) | 2000-06-13 | 2003-03-06 | 와이어쓰 | Ｃｏｘ-２저해제를 함유하는 진통성 및 항-염증성 조성물 |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| ATE420201T1 (de) | 2000-08-07 | 2009-01-15 | Univ Vanderbilt | Nachweis der cox-2 aktivität und von anandamid- metaboliten |
| AU2002354901A1 (en) * | 2001-07-16 | 2003-03-03 | Edward Hogestatt | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| WO2004098619A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| WO2005009436A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| WO2006123247A2 (en) * | 2005-05-20 | 2006-11-23 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands |
| EP2061440A2 (en) | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| CA2942083C (en) | 2007-04-26 | 2019-01-29 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| CN102470106B (zh) | 2009-05-18 | 2015-09-23 | 希格默伊德药业有限公司 | 包含油滴的组合物 |
| CA2770570A1 (en) | 2009-08-12 | 2011-02-17 | Sigmoid Pharma Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR102270323B1 (ko) | 2014-03-06 | 2021-06-29 | 아라타나 세라퓨틱스, 인크. | 그라피프란트의 조성물 및 이를 사용하기 위한 방법 |
| BR112017009510A2 (pt) | 2014-11-07 | 2017-12-19 | Sigmoid Pharma Ltd | composições compreendendo ciclosporina |
| WO2016112312A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/xx active
- 1998-04-30 TW TW087106689A patent/TW590773B/zh not_active IP Right Cessation
- 1998-05-01 YU YU55899A patent/YU55899A/sh unknown
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/hu unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/ja active Pending
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Ceased
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 EA EA199900895A patent/EA003696B1/ru not_active IP Right Cessation
- 1998-05-01 SK SK1481-99A patent/SK148199A3/sk unknown
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 IL IL13257098A patent/IL132570A0/xx unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/ko not_active Ceased
- 1998-05-01 CN CN98804845A patent/CN1255059A/zh active Pending
- 1998-05-01 ID IDP980651A patent/ID21311A/id unknown
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/pt not_active IP Right Cessation
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/ko not_active Ceased
- 1998-05-01 PL PL98337003A patent/PL337003A1/xx unknown
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-04 GT GT199800063A patent/GT199800063A/es unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/es not_active Application Discontinuation
- 1998-05-04 MA MA25059A patent/MA26491A1/fr unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/xx unknown
- 1998-05-04 PE PE1998000335A patent/PE72599A1/es not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/fr unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/hr not_active Application Discontinuation
- 1998-05-05 AR ARP980102089A patent/AR011726A1/es unknown
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/es unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/is unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/xx unknown
- 1999-11-04 NO NO995389A patent/NO995389L/no not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039628A2 (es) | Formulacion masticable de carprofeno, implante y composicion terapeutica | |
| AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
| RU97117350A (ru) | Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
| AR020688A1 (es) | Derivados de la imidazo [4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones f | |
| MY106552A (en) | Novel pyrido[2,3-f] [1,4]thiazepines and pyrido[3,2-b] [1,5] benzothiazepines. | |
| AR009484A1 (es) | Un compuesto de acido n-sustituido-2-amino-4-fenil-4-oxo-butanoico, su utilizacion como inhibidor de la quinurenina-3-hidroxilasa y una composicionfarmaceutica que lo comprende. | |
| DE60003194D1 (de) | Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren | |
| AR008494A1 (es) | Empleo de las pirazolinonas para el tratamiento de los trastornos de la potencia, preparaciones farmaceuticas que las contienen, empleo de estaspreparaciones farmaceuticas para el tratamiento y/o la terapia de los trastornos de la potencia y un procedimiento para prepararlas | |
| SE0104333D0 (sv) | Therapeutic agents | |
| DE69523581D1 (de) | Anti-helicobacter ester- oder carbamatderivate von azolonen | |
| CO5271694A1 (es) | Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion | |
| PE20050139A1 (es) | Compuestos derivados de acidos hidroxamicos y composiciones farmaceuticas | |
| SE9900190D0 (sv) | New compounds | |
| ES2095714T3 (es) | Nuevas amino-alquil-cromonas, sus procedimientos de preparacion y las composiciones farmaceuticas que las contienen. | |
| NO171363C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive oksysalicylaminoderivater | |
| IT1244696B (it) | Derivato chinolonico ad attivita' antibatterica e mucolitica | |
| DK1065206T3 (da) | Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler | |
| CU23156A3 (es) | ANáLOGOS GABA PARA PREVENIR Y TRATAR DANOS GASTROINTESTINALES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |